{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:00:18Z","timestamp":1793228418508,"version":"4.5.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,4]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Myeloma cells produce ammonium in the presence of glutamine, showing high glutaminase and low glutamine synthetase expression. Myeloma cells show high expression of glutamine transporters and inhibition of ASCT2 transporter hinders myeloma growth.<\/jats:p>","DOI":"10.1182\/blood-2016-01-690743","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T23:53:37Z","timestamp":1465257217000},"page":"667-679","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":170,"title":["Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target"],"prefix":"10.1182","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0821-8093","authenticated-orcid":false,"given":"Marina","family":"Bolzoni","sequence":"first","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-9984","authenticated-orcid":false,"given":"Martina","family":"Chiu","sequence":"additional","affiliation":[{"name":"Unit of General Pathology, Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Accardi","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"},{"name":"Hematology and BMT Center, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Vescovini","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Airoldi","sequence":"additional","affiliation":[{"name":"Laboratorio di Oncologia, Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"},{"name":"CoreLab, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Todoerti","sequence":"additional","affiliation":[{"name":"Laboratory of Pre-clinical and Translational Research, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Agnelli","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Missale","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit and Hepatology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Andreoli","sequence":"additional","affiliation":[{"name":"Unit of Occupational Medicine, Department of Clinical and Experimental Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4179-6573","authenticated-orcid":false,"given":"Massimiliano G.","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Unit of General Pathology, Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italy;"},{"name":"Unit of Occupational Medicine, Department of Clinical and Experimental Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Allegri","sequence":"additional","affiliation":[{"name":"Unit of General Pathology, Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Barilli","sequence":"additional","affiliation":[{"name":"Unit of General Pathology, Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertina","family":"Cavalli","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit and Hepatology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Costa","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Marchica","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"},{"name":"CoreLab, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Toscani","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mancini","sequence":"additional","affiliation":[{"name":"U.O. di Anatomia Patologica, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Martella","sequence":"additional","affiliation":[{"name":"U.O. di Anatomia Patologica, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Dall\u2019Asta","sequence":"additional","affiliation":[{"name":"Unit of General Pathology, Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Donofrio","sequence":"additional","affiliation":[{"name":"Department of Medical-Veterinary Science, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Aversa","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"},{"name":"Hematology and BMT Center, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-2939","authenticated-orcid":false,"given":"Ovidio","family":"Bussolati","sequence":"additional","affiliation":[{"name":"Unit of General Pathology, Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-3774","authenticated-orcid":false,"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Department of Clinical and Experimental Medicine, and"},{"name":"Hematology and BMT Center, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"},{"name":"CoreLab, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111903083028900_B1","doi-asserted-by":"crossref","first-page":"xi","DOI":"10.1016\/j.hoc.2014.08.001","article-title":"Multiple myeloma.","volume":"28","author":"Anderson","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"2019111903083028900_B2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma.","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"2019111903083028900_B3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4684-3264-0_13","article-title":"Amino acid transport in spinal and sympathetic ganglia.","volume":"69","author":"Roberts","year":"1976","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"2019111903083028900_B4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.leu.2401077","article-title":"In vitro excess ammonia production in human myeloma cell lines.","volume":"12","author":"Otsuki","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"2019111903083028900_B5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2169\/internalmedicine.31.339","article-title":"Human myeloma cell line (KHM-4) established from a patient with multiple myeloma associated with hyperammonemia.","volume":"31","author":"Matsuzaki","year":"1992","journal-title":"Intern Med"},{"issue":"6","key":"2019111903083028900_B6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3816\/CLM.2008.n.054","article-title":"Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases.","volume":"8","author":"Lora-Tamayo","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"2019111903083028900_B7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0925-5710(95)00359-Z","article-title":"Serum amino acid disturbance in multiple myeloma with hyperammonemia.","volume":"61","author":"Matsuzaki","year":"1995","journal-title":"Int J Hematol"},{"issue":"21","key":"2019111903083028900_B8","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1056\/NEJM200205233462119","article-title":"Hyperammonemic encephalopathy in multiple myeloma.","volume":"346","author":"Kwan","year":"2002","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111903083028900_B9","first-page":"557","article-title":"Hyperammonemic encephalopathy in multiple myeloma.","volume":"9","author":"Furer","year":"2007","journal-title":"Isr Med Assoc J"},{"issue":"5","key":"2019111903083028900_B10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ajh.20808","article-title":"Hyperammonemia and encephalopathy in patients with multiple myeloma.","volume":"82","author":"Talamo","year":"2007","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111903083028900_B11","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/j.1532-5415.2010.02994.x","article-title":"Multiple myeloma presenting as hyperammonemic encephalopathy.","volume":"58","author":"B\u00e9net","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2019111903083028900_B12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.leukres.2013.07.014","article-title":"Multiple myeloma-induced hyperammonemic encephalopathy: an entity associated with high in-patient mortality.","volume":"37","author":"Pham","year":"2013","journal-title":"Leuk Res"},{"issue":"17","key":"2019111903083028900_B13","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-12-2917","article-title":"Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission.","volume":"19","author":"Puchades-Carrasco","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111903083028900_B14","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.metabol.2012.07.007","article-title":"Ammonium metabolism in humans.","volume":"61","author":"Adeva","year":"2012","journal-title":"Metabolism"},{"issue":"8","key":"2019111903083028900_B15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: a new therapeutic target in cancer.","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem Sci"},{"key":"2019111903083028900_B16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fchem.2014.00061","article-title":"Membrane transporters for the special amino acid glutamine: structure\/function relationships and relevance to human health.","volume":"2","author":"Pochini","year":"2014","journal-title":"Front Chem"},{"issue":"2","key":"2019111903083028900_B17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.abb.2008.01.026","article-title":"Highlights of glucosamine-6P synthase catalysis.","volume":"474","author":"Durand","year":"2008","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"2019111903083028900_B18","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI78239","article-title":"Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.","volume":"125","author":"Tanaka","year":"2015","journal-title":"J Clin Invest"},{"key":"2019111903083028900_B19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/msb.20134892","article-title":"Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.","volume":"10","author":"Yang","year":"2014","journal-title":"Mol Syst Biol"},{"issue":"10","key":"2019111903083028900_B20","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.18632\/oncotarget.3132","article-title":"Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma.","volume":"6","author":"Ratnikov","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"2019111903083028900_B21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.18632\/oncotarget.2708","article-title":"Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.","volume":"6","author":"Fogal","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"2019111903083028900_B22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2174\/156800911797264725","article-title":"L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of \u03b2-catenin-mutated human hepatocellular carcinoma cells.","volume":"11","author":"Tardito","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"issue":"9","key":"2019111903083028900_B23","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1158\/0008-5472.CAN-14-3745","article-title":"Amino acid transporters in cancer and their relevance to \u201cglutamine addiction\u201d: novel targets for the design of a new class of anticancer drugs.","volume":"75","author":"Bhutia","year":"2015","journal-title":"Cancer Res"},{"issue":"3","key":"2019111903083028900_B24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-12-2334","article-title":"SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.","volume":"19","author":"Hassanein","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111903083028900_B25","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/bjc.2014.425","article-title":"Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts.","volume":"111","author":"Chiu","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"2019111903083028900_B26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"2019111903083028900_B27","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2013-03-493163","article-title":"Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.","volume":"122","author":"Willems","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111903083028900_B28","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111903083028900_B29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/cas.12807","article-title":"A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.","volume":"106","author":"Sugimoto","year":"2015","journal-title":"Cancer Sci"},{"issue":"7","key":"2019111903083028900_B30","first-page":"2423","article-title":"Asparaginases: biochemical pharmacology and modes of drug resistance.","volume":"32","author":"Avramis","year":"2012","journal-title":"Anticancer Res"},{"issue":"2","key":"2019111903083028900_B31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"issue":"23","key":"2019111903083028900_B32","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2013-10-535112","article-title":"The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.","volume":"123","author":"Chan","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111903083028900_B33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111903083028900_B34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma.","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2019111903083028900_B35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/leu.2012.190","article-title":"Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a\/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.","volume":"27","author":"Bolzoni","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2019111903083028900_B36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/leu.2015.259","article-title":"Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.","volume":"30","author":"Palma","year":"2016","journal-title":"Leukemia"},{"issue":"16","key":"2019111903083028900_B37","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.1158\/1078-0432.CCR-04-2685","article-title":"Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.","volume":"11","author":"Buzzeo","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2019111903083028900_B38","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.","volume":"267","author":"O\u2019Brien","year":"2000","journal-title":"Eur J Biochem"},{"issue":"4 Pt 1","key":"2019111903083028900_B39","doi-asserted-by":"crossref","first-page":"C865","DOI":"10.1152\/ajpcell.1999.276.4.C865","article-title":"Amino acids are compatible osmolytes for volume recovery after hypertonic shrinkage in vascular endothelial cells.","volume":"276","author":"Dall\u2019Asta","year":"1999","journal-title":"Am J Physiol"},{"issue":"12","key":"2019111903083028900_B40","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-12-3461","article-title":"Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.","volume":"19","author":"Todoerti","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"27","key":"2019111903083028900_B41","doi-asserted-by":"crossref","first-page":"24205","DOI":"10.18632\/oncotarget.4434","article-title":"Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.","volume":"6","author":"Lionetti","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"2019111903083028900_B42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/jme.0.0250169","article-title":"Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays.","volume":"25","author":"Bustin","year":"2000","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"2019111903083028900_B43","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.neuroscience.2007.11.055","article-title":"C6 glioma cells differentiated by retinoic acid overexpress the glutamate transporter excitatory amino acid carrier 1 (EAAC1).","volume":"151","author":"Bianchi","year":"2008","journal-title":"Neuroscience"},{"key":"2019111903083028900_B44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jchromb.2012.07.038","article-title":"A HILIC-MS\/MS method for the simultaneous determination of seven organic acids in rat urine as biomarkers of exposure to realgar.","volume":"905","author":"Huang","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"8","key":"2019111903083028900_B45","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/leu.2013.24","article-title":"Hypoxia-inducible factor (HIF)-1\u03b1 suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.","volume":"27","author":"Storti","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2019111903083028900_B46","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/jn\/137.6.1357","article-title":"Glutamine directly downregulates glutamine synthetase protein levels in mouse C2C12 skeletal muscle myotubes.","volume":"137","author":"Huang","year":"2007","journal-title":"J Nutr"},{"issue":"5 Pt 1","key":"2019111903083028900_B47","first-page":"L877","article-title":"Glutamine synthetase expression in rat lung is regulated by protein stability.","volume":"275","author":"Labow","year":"1998","journal-title":"Am J Physiol"},{"issue":"6 Pt 1","key":"2019111903083028900_B48","first-page":"E1136","article-title":"Glutamine synthetase expression in muscle is regulated by transcriptional and posttranscriptional mechanisms.","volume":"276","author":"Labow","year":"1999","journal-title":"Am J Physiol"},{"issue":"3","key":"2019111903083028900_B49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/BJ20070039","article-title":"Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).","volume":"406","author":"Robinson","year":"2007","journal-title":"Biochem J"},{"issue":"23","key":"2019111903083028900_B50","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1158\/1078-0432.CCR-11-0596","article-title":"The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma.","volume":"17","author":"Agnelli","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111903083028900_B51","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1001\/jamainternmed.2015.5772","article-title":"The Importance of Clinical Context When Interpreting Serum Ammonia Levels: A Teachable Moment.","volume":"175","author":"Howells","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2019111903083028900_B52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.15430\/JCP.2013.18.3.221","article-title":"Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells.","volume":"18","author":"Kim","year":"2013","journal-title":"J Cancer Prev"},{"issue":"4","key":"2019111903083028900_B53","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.drudis.2013.10.008","article-title":"Glutaminase regulation in cancer cells: a druggable chain of events.","volume":"19","author":"Katt","year":"2014","journal-title":"Drug Discov Today"},{"issue":"2-3","key":"2019111903083028900_B54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.mam.2012.07.012","article-title":"Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects.","volume":"34","author":"Schi\u00f6th","year":"2013","journal-title":"Mol Aspects Med"},{"issue":"1","key":"2019111903083028900_B55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00726-011-0862-x","article-title":"Regulation of xCT expression and system x (c) (-) function in neuronal cells.","volume":"42","author":"Lewerenz","year":"2012","journal-title":"Amino Acids"},{"issue":"1","key":"2019111903083028900_B56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"2019111903083028900_B57","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4720.4720","article-title":"Glutaminase inhibitor CB-839 synergizes with pomalidomide in preclinical multiple myeloma models [abstract].","volume":"124","author":"Parlati","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111903083028900_B58","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood.V126.23.3059.3059","article-title":"Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma.","volume":"126","author":"Vogl","year":"2015","journal-title":"Blood"},{"key":"2019111903083028900_B59","author":"Bajpai"},{"issue":"5","key":"2019111903083028900_B60","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.","volume":"21","author":"Dalva-Aydemir","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/5\/667\/1397984\/667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/5\/667\/1397984\/667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:09:00Z","timestamp":1574132940000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/5\/667\/35559\/Dependence-on-glutamine-uptake-and-glutamine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,8,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-01-690743","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]}}}